Bears REASONS TO SELL
March 10, 2014
(Jutia Group, 2/10/14)
[Business Wire] - Gilead Sciences, Inc. today announced that the company has submitted a New Drug...(read more)
(Stock Blog Hub, 12/14/13)
One of the big winners of Obamacare will be the pharmaceutical industry. Despite new highs for most big pharma companies – they are currently sitting at prices we haven’t seen in a decade –...(read more)
(The Market Financial, 12/10/13)
There has been constant talk about the overall market being in a bubble. Is it a bubble? To some extent yes, however there is one particular sector that is in the...(read more)
Gilead Sciences (GILD) Company Overview
Gilead Sciences (NYSE: GILD) is a biopharmaceutical company that specializes in the development and commercialization of drugs for the treatment of HIV infection, hepatitis B infection (HBV), cystic fibrosis, fungal infections, and influenza A and B. The company currently produces a market-leading HIV drug portfolio as well as other drugs, which face strong competition from drug-makers such as GlaxoSmithKline (GSK), Novartis AG (NVS), Merck (MRK), Enzon Pharmaceuticals (ENZN), and Bristol-Myers Squibb Company (BMY).In 2010, Gilead generated $7.95 billion in revenues and net earnings of $2.9 billion.
Gilead's profitability can be potentially affected by various factors, including legislative and regulatory changes in federal and private insurance coverage of its drug products, competition from the development of generic drug substitutes, supply shortages of active ingredients in its drugs, the success of clinical trials of newly-developed drugs, and changes in FDA regulations.(Read more at Wikinvest )
What's in this GILD analysis on Wikinvest...